Sirolimus telehealth options: what you're actually buying

Last updated 2026-07-30

What is sirolimus telehealth, exactly?

Sirolimus telehealth is a service model, not a drug or a clinical trial. You fill out an intake form, maybe do a video call, a prescriber (often a nurse practitioner working under a supervising physician, sometimes a physician directly) reviews your history and orders labs, and if they sign off, a pharmacy ships you sirolimus tablets or a compounded capsule. The whole thing happens outside a traditional in-person clinic visit. The drug itself is not new or exotic. Sirolimus (brand name Rapamune) got FDA approval in 1999 to prevent organ rejection in kidney transplant patients ^[1]. It's chemically identical to rapamycin, isolated originally from soil bacteria on Rapa Nui (Easter Island), and the two names get used interchangeably in the longevity world. Other approved uses include Fyarro (albumin-bound sirolimus, for a rare cancer called malignant PEComa) and Hyftor (topical sirolimus gel for facial angiofibromas in tuberous sclerosis) ^[2]. None of the FDA labels say anything about aging, lifespan, or healthspan. Every telehealth prescription for longevity purposes is off-label, full stop. That's not automatically a red flag. Off-label prescribing is legal and common in American medicine; doctors prescribe beta blockers for anxiety and gabapentin for pain constantly. But it does mean the telehealth company's marketing claims and the FDA's actual approved indications are two completely different documents. Read the label, not the landing page.

How does the intake and prescribing process actually work?

Most sirolimus telehealth platforms follow a similar funnel: online questionnaire, sometimes a required video visit, baseline labs (usually a CBC, metabolic panel, lipid panel, and sometimes a specific request for fasting glucose or HbA1c), then a prescription if the prescriber approves. Follow-up labs at 3 to 6 months are common, since sirolimus can raise triglycerides and cholesterol and occasionally affects blood counts ^[3]. The prescriber matters more than people assume. Under most state nurse practice acts, NPs can prescribe controlled and non-controlled medications, but the required physician supervision or collaborative agreement varies by state, and telehealth companies structure around whichever states let them scale fastest. Ask directly: who is prescribing, are they licensed in my state, and is there a real human reviewing my labs, or is this a rubber stamp. A good service will answer without hesitation. Compounded versus manufactured product is another split. Some telehealth pharmacies dispense generic sirolimus tablets (FDA-approved formulation, has an NDC number, goes through standard generic manufacturing quality checks). Others dispense compounded capsules from a 503A or 503B pharmacy, which are not FDA-approved products and don't go through the same batch testing. Compounding can be legitimate and necessary for custom doses, but it's a different risk category than filling an approved generic, and the FDA has issued warnings about quality problems at specific compounding pharmacies in the past ^[4]. Ask which one you're getting.

What does sirolimus telehealth actually cost?

Pricing varies by weight-based dose, brand versus generic, and whether a subscription bundles in labs and consults. Generic sirolimus tablets, paid out of pocket without insurance, commonly run somewhere in the $100 to $400 per month range depending on dose and pharmacy, based on typical cash-pay generic drug pricing patterns reported by GoodRx-type discount services (check current pricing directly, as it shifts). Compounded formulations and subscription telehealth bundles that include the consult and periodic labs often land in a similar or higher band, commonly cited in the $150 to $300+/month range once the service fee is included. Insurance almost never covers this. Sirolimus is only covered for its approved indications (transplant rejection prophylaxis, PEComa, tuberous sclerosis-related conditions). An off-label longevity prescription will be denied or simply never submitted, meaning you're paying cash for the drug, the consult fee, and the lab work unless you route labs through your own insurance separately. Budget for the real total: drug cost, telehealth platform fee (often a subscription, $20 to $50/month is a common range for the platform itself on top of drug cost), and periodic lab panels ($50 to $200 out of pocket if not covered, more if using a specialty panel). Nobody is publishing an industry-wide average because prices change fast and companies don't disclose them consistently, so get a specific quote before you commit.

Is there actual human evidence that sirolimus extends lifespan?

No. There is no completed human trial showing sirolimus or rapamycin extends lifespan or healthspan in otherwise healthy adults. This is the single most important fact in this entire space, and it's worth restating every time someone brings up the mouse data. The strongest evidence comes from the National Institute on Aging's Interventions Testing Program (ITP), which has tested rapamycin across three independent lab sites in genetically heterogeneous mice since 2006. Rapamycin extended median lifespan in both sexes, with effects seen even when dosing started later in life (starting at 600 days of age, roughly human late-middle-age equivalent) ^[5]. A widely cited ITP result showed roughly 9-14% median lifespan extension in male mice and larger effects in females at certain doses, with the exact percentage depending on the specific cohort, dose, and sex studied. This is genuinely one of the most well-replicated results in the entire aging-intervention literature; it held up across sites and dose levels, which is rare. What doesn't exist yet is the human version of that trial. The PEARL trial (a University of California, Los Angeles-affiliated study on low-dose rapamycin in healthy older adults) has published early data on tolerability and some biomarkers, but it is not a lifespan trial and cannot be, since human lifespan trials would take decades to read out ^[6]. There is no way, currently, to run a true human lifespan RCT for rapamycin in a reasonable timeframe. Everything sold on telehealth platforms for longevity is extrapolated from mouse biology, mTOR pathway mechanism, and short-term human safety and biomarker data. That's a real scientific foundation, but it is not proof of human lifespan extension. If a telehealth site implies otherwise, that's marketing outrunning the data. For deeper background on what the actual before-and-after data looks like in the humans who have taken it, see sirolimus before and after and the sirolimus results timeline.

What are the real risks of off-label, intermittent-dose sirolimus?

The FDA label lists sirolimus as an immunosuppressant, and that's true regardless of the dose or schedule a longevity clinic uses. The longevity community's popular workaround is intermittent dosing (once weekly or every-other-week, rather than the daily transplant-rejection dose) on the theory that pulsed dosing hits mTORC1 without the sustained immune suppression of daily dosing. That idea has some mechanistic support and some human biomarker data behind it, but it has not been proven to eliminate risk. Immunosuppression is the headline risk. Even weekly dosing can blunt some immune responses, and transplant-dose data shows higher infection rates as a class effect of mTOR inhibitors ^[3]. Mouth ulcers (stomatitis) are the most commonly reported side effect in clinical trials of sirolimus, hitting a meaningful minority of patients at transplant doses, and they show up at lower intermittent doses too, according to patient reports and small studies ^[3]. Metabolic effects are real and measurable: sirolimus can raise LDL cholesterol and triglycerides and has been associated with new-onset insulin resistance in some transplant patients, which is exactly why baseline and follow-up lipid and glucose panels matter ^[3]. Other documented risks at approved doses include delayed wound healing, low white blood cell or platelet counts, and rare but serious lung inflammation (interstitial lung disease) ^[3]. None of these risks disappear because a dose is small or infrequent; they just become less frequent and less severe, based on the limited human safety data available. Nobody has a large, long-term safety dataset for low-dose intermittent rapamycin in healthy adults, because that trial hasn't been run. If a telehealth intake doesn't ask about live vaccines, current infections, planned surgery, or pregnancy, that's a real gap. All of those interact with an immunosuppressant, even at low doses.

How do I evaluate a telehealth provider before I hand over my card?

Treat this like vetting any prescriber, not like buying a subscription box. A few concrete checks: License and state match: confirm the prescriber is licensed in your state. Telehealth prescribing generally requires the prescriber to be licensed where the patient is physically located, a rule enforced through state medical and nursing boards, not a federal telehealth-specific statute. Ask the platform directly if you can't find it on their site. Lab requirements: a provider who never asks for baseline labs (CBC, lipid panel, metabolic panel at minimum) before prescribing an immunosuppressant is skipping a step that matters. Follow-up labs at 3-6 months should be part of the plan, not an upsell. Drug source transparency: ask whether you're getting FDA-approved generic sirolimus or a compounded version, and from which pharmacy. A provider-reviewed model that names its fulfilling pharmacy partner openly is giving you more information than one that's vague about sourcing. Sirolimus Rx operates this way: it connects patients to provider review and names the pharmacy that fills the prescription, rather than compounding or manufacturing anything itself. Honesty about the evidence gap: does the intake material or consult mention that there's no completed human lifespan trial? If a service talks only about the mouse data and skips that caveat, that's a marketing tell, not a medical one. Cancellation and refund terms: subscription models should let you cancel before the next fill and refund unopened, unshipped orders per standard pharmacy return policy (opened prescription medication generally cannot be returned once dispensed, per standard pharmacy practice).

What questions should I ask before my first telehealth visit?

Bring a short list and actually ask it out loud or in the intake notes field. Useful ones: What dose and schedule are you starting me on, and why that one? What labs will you want before and after? Is this sirolimus tablets (generic Rapamune) or a compounded formulation, and from which pharmacy? What side effects should make me stop and call you? Do you check for interactions with my other medications (sirolimus interacts with strong CYP3A4 inhibitors and inducers, among other drugs) ^[3]? Also ask what happens if labs come back abnormal. A provider who has a clear answer (dose adjustment, hold the drug, refer out) is different from one who seems to be following a script. And ask directly: has this platform run its own outcomes data, or is it relying entirely on the ITP mouse studies and PEARL trial data for its claims? Most will say the latter, and that's fine, as long as they say it. If you're still deciding whether the whole category makes sense for you, read through sirolimus pros and cons and is sirolimus worth it before you spend money on labs and a consult fee.

Sirolimus telehealth vs. in-person longevity clinic vs. asking your own doctor: how do they compare?

Is sirolimus telehealth legal, and is it regulated the same way everywhere?

Yes, telehealth prescribing of an FDA-approved drug for an off-label use is legal in the United States, provided the prescriber is licensed, follows their state's telehealth practice rules, and the patient consents to off-label use with informed understanding. This is the same legal framework that allows off-label GLP-1, off-label low-dose naltrexone, and plenty of other telehealth categories to operate. Where it gets state-specific is prescriber supervision requirements and whether an initial video visit is mandated versus a questionnaire alone. Some states require a synchronous audio-video visit before an initial controlled-substance or certain drug prescriptions; sirolimus is not a controlled substance under the federal Controlled Substances Act schedules, which gives telehealth platforms more flexibility than they'd have with, say, a stimulant ^[7]. Ryan Haight Act rules, which govern remote prescribing of controlled substances, do not apply to sirolimus for that reason. None of that legality speaks to whether the off-label use itself is well-supported by data. It's legal to prescribe sirolimus for longevity purposes. It is not FDA-approved for that purpose, and no professional society (American Geriatrics Society, Endocrine Society, or similar) has issued a formal guideline recommending it for healthy adults seeking lifespan extension.

What should I actually do with this information?

If you're set on trying sirolimus off-label, go in with eyes open: get baseline labs, use a service that discloses its pharmacy and prescriber credentials, and repeat labs on schedule rather than skipping them to save money. Read the mouse data for what it is (some of the best replicated aging-intervention evidence that exists) and the human data for what it is (short-term safety and biomarker signals, no lifespan outcome, ever, so far) ^{[5] [6]}. Don't buy from a source that won't tell you who's prescribing or what pharmacy fills the order. Don't skip labs to save $100 on an immunosuppressant. And don't let anyone, telehealth platform or otherwise, tell you the human lifespan trial exists. It doesn't yet. For a wider read on what people report after months or years on the drug, sirolimus reviews and the sirolimus success rate page cover the self-reported side of the picture, separate from the clinical trial data covered here.

Frequently asked questions

Can I get sirolimus prescribed through telehealth without an in-person visit?

Often yes. Many telehealth platforms prescribe sirolimus for off-label longevity use based on an online intake form, sometimes with a video visit, plus lab work. Requirements vary by state and by platform; some mandate a live video consult before the first prescription, others don't. Confirm the specific platform's process and your state's telehealth prescribing rules before assuming a purely asynchronous path applies to you.

Is sirolimus telehealth legal in the US?

Yes. Off-label prescribing of an FDA-approved drug through telehealth is legal, provided the prescriber is licensed in the patient's state. Sirolimus is not a federally controlled substance, so it isn't subject to the stricter Ryan Haight Act video-visit requirements that apply to controlled substances. Legality doesn't equal proven efficacy for longevity use, which remains entirely off-label and unapproved by the FDA.

How much does sirolimus cost through telehealth per month?

Generic sirolimus tablets commonly cost roughly $100-$400/month out of pocket depending on dose, based on typical cash-pay generic pricing. Telehealth subscription models bundling the consult, drug, and periodic labs often land around $150-$300+/month total. Insurance essentially never covers off-label longevity prescriptions, so expect to pay cash for the drug, platform fee, and lab panels.

Does insurance cover sirolimus for anti-aging use?

No. Insurance covers sirolimus only for its FDA-approved indications: kidney transplant rejection prophylaxis, and specific formulations for malignant PEComa (Fyarro) or tuberous sclerosis-related skin lesions (Hyftor). Off-label longevity prescriptions are not a covered indication under any standard health plan, so expect to pay the full cash price for the drug, consult, and labs.

What labs do I need before starting sirolimus?

Reputable telehealth prescribers typically require a baseline CBC (complete blood count), a metabolic panel, and a lipid panel before starting, with follow-up labs at 3-6 months. This matters because sirolimus can affect white blood cell and platelet counts, raise LDL cholesterol and triglycerides, and in some cases affect glucose metabolism, per the FDA label's documented adverse effects.

Is rapamycin the same as sirolimus?

Yes, they're the same molecule. Rapamycin is the generic/scientific name; sirolimus is the pharmaceutical name used on the FDA-approved label (brand name Rapamune). Telehealth platforms and longevity researchers use the terms interchangeably, and any prescription for one is a prescription for the other.

Has sirolimus been proven to extend human lifespan?

No. There is no completed human trial showing sirolimus extends lifespan. The strong evidence is in mice, via the NIA Interventions Testing Program, which found consistent lifespan extension across independent lab sites. Human data (like the PEARL trial) covers short-term safety and biomarkers only, not lifespan outcomes, because a human lifespan RCT would take decades to complete.

What are the main side effects of low-dose intermittent sirolimus?

The most commonly reported side effects, even at low intermittent doses, are mouth ulcers (stomatitis), elevated cholesterol and triglycerides, and some degree of immune suppression. Rarer but documented risks at approved doses include low blood counts, delayed wound healing, and interstitial lung disease. Nobody has large long-term safety data specifically for low-dose intermittent dosing in healthy adults.

Can a nurse practitioner prescribe sirolimus through telehealth?

In most states, yes, within their scope of practice and any required physician collaboration agreement, which varies by state nurse practice act. Sirolimus isn't a controlled substance, so NP prescribing authority for it generally follows the same rules as other non-controlled prescription drugs in that state. Ask the platform directly which state licenses its prescribers hold.

Is compounded sirolimus different from the FDA-approved version?

Yes. FDA-approved sirolimus (generic Rapamune) goes through standard manufacturing quality controls and has an NDC number. Compounded sirolimus is prepared by a 503A or 503B pharmacy for individualized dosing and is not itself FDA-approved as a finished product, meaning it doesn't undergo the same batch testing. Ask any telehealth provider which type you're being prescribed.

Does sirolimus interact with other medications?

Yes. Sirolimus is metabolized via CYP3A4, so strong inhibitors (like certain antifungals) or inducers (like some anticonvulsants) can significantly raise or lower blood levels, per the FDA prescribing information. Grapefruit juice is also a known interaction. Always give a telehealth prescriber a full medication list, including supplements, before starting.

How is telehealth sirolimus different from getting it at an in-person longevity clinic?

Telehealth is usually faster and cheaper per month, but consult depth varies by platform. In-person longevity clinics often provide more extensive lab panels and face-to-face time but typically cost more (often $300-$1,000+/month when bundled with other interventions). Neither route has access to human lifespan outcome data that doesn't currently exist.

Sources

1. FDA, Rapamune (sirolimus) approval history: Sirolimus (Rapamune) received FDA approval in 1999 for kidney transplant rejection prophylaxis
2. FDA, Fyarro and Hyftor prescribing information: Sirolimus-based products Fyarro and Hyftor are approved for malignant PEComa and tuberous sclerosis-related skin lesions, not for aging or lifespan
3. FDA, Rapamune prescribing information (label): Sirolimus label documents mouth ulcers, elevated lipids, low blood counts, delayed wound healing, and interstitial lung disease as adverse effects, plus CYP3A4 drug interactions
4. FDA, compounding and 503A/503B pharmacy oversight: Compounded drug products are not FDA-approved and are prepared under different oversight than manufactured generics
5. Harrison DE et al., Nature, NIA Interventions Testing Program rapamycin lifespan study: NIA Interventions Testing Program found rapamycin extended median lifespan in genetically heterogeneous mice across independent lab sites, including when started later in life
6. Kaeberlein Lab / PEARL trial, University of Washington: The PEARL trial studies low-dose rapamycin safety and biomarkers in healthy older adults but is not a lifespan outcome trial
7. DEA, Controlled Substances Act schedules: Sirolimus is not listed as a controlled substance under the federal Controlled Substances Act, affecting telehealth prescribing rules